Jennifer H. Carroll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer H. Carroll has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Avril Collinson
School of Health Professions, Faculty of Health, University of Plymouth, Devon, United Kingdom
4 shared publicationsEmma Williams
Matthew's Friends, Lingfield, Surrey, United Kingdom
3 shared publications- Judith Helen Cross
University College London National Institute for Health and Care Research Biomedical Research Centres Great Ormond Street Institute of Child Health London UK
3 shared publications - Mary Hickson
University of Plymouth
3 shared publications Val Aldridge
Matthew's Friends, Lingfield, Surrey, United Kingdom
3 shared publications- Kirsty J. Martin-McGill
Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Lower Lane Liverpool UK L9 7LJ
2 shared publications
Latest Publications
- Open Access
- 8 September 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 172, 110683
Over twenty-five years of ketogenic diet therapy: Supporting children and adults with drug-resistant epilepsy using nutritionally complete ketogenic formulations: A scoping review
- 8 September 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 172, 110683
Open AccessOver twenty-five years of ketogenic diet therapy: Supporting children and adults with drug-resistant epilepsy using nutritionally complete ketogenic formulations: A scoping review
- Open Access
- 25 April 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 118, 137-147
Drug-resistant epilepsy and ketogenic diet therapy – a qualitative study of families’ experiences
- 25 April 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 118, 137-147
Open AccessDrug-resistant epilepsy and ketogenic diet therapy – a qualitative study of families’ experiences
- Open Access
A core outcome set for childhood epilepsy treated with ketogenic diet therapy (CORE‐KDT study): International parent and health professional consensus
Objective: Ketogenic diet therapy (KDT) can result in benefits (seizure‐related and non‐seizure‐related) for children with drug‐resistant epilepsy. However, clinical trials report a wide range of outcomes, making synthesis of evidence difficult, and do not adequately reflect parent views on important outcomes for their child. To address this, we established the first international parent, health professional, and researcher consensus to develop a core outcome set, guided by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative (COMET registration #1116).Methods: Ethical approval was granted (London–Surrey REC19/LO/1680). A scoping review and interviews with parents identified a comprehensive list of potentially important outcomes, followed by a two‐round online Delphi survey of parents and health professionals to prioritize outcomes of importance for inclusion in a core outcome set. This informed a stakeholder consensus meeting and consultation process to finalize the core outcome set.Results: In total, 97 outcomes were identified; 90 from the scoping review and seven from parent interviews. These were rationalized to 77 by the study advisory group, then rated in the first Delphi round by 49 parents and 96 health professionals, who suggested 12 new outcomes for rating in Round 2. Sixty‐six percent of participants (30 parents and 66 professionals) completed Round 2, where 22 outcomes met criteria for inclusion. In the consensus meeting (nine parents and 13 professionals), 27 undecided outcomes were discussed and scored; one further outcome reached consensus for inclusion. After consultation and ratification, 14 outcomes across five domains were included in the core outcome set.Significance: A core outcome set for childhood epilepsy treated with KDT has been developed, incorporating the views of international parents and professionals. Implementation in research and clinical settings will standardize outcome selection and reporting, facilitate data synthesis, and ultimately enhance the relevance of outcomes to parents, researchers, and health professionals.
Open AccessA core outcome set for childhood epilepsy treated with ketogenic diet therapy (CORE‐KDT study): International parent and health professional consensus
Objective: Ketogenic diet therapy (KDT) can result in benefits (seizure‐related and non‐seizure‐related) for children with drug‐resistant epilepsy. However, clinical trials report a wide range of outcomes, making synthesis of evidence difficult, and do not adequately reflect parent views on important outcomes for their child. To address this, we established the first international parent, health professional, and researcher consensus to develop a core outcome set, guided by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative (COMET registration #1116).Methods: Ethical approval was granted (London–Surrey REC19/LO/1680). A scoping review and interviews with parents identified a comprehensive list of potentially important outcomes, followed by a two‐round online Delphi survey of parents and health professionals to prioritize outcomes of importance for inclusion in a core outcome set. This informed a stakeholder consensus meeting and consultation process to finalize the core outcome set.Results: In total, 97 outcomes were identified; 90 from the scoping review and seven from parent interviews. These were rationalized to 77 by the study advisory group, then rated in the first Delphi round by 49 parents and 96 health professionals, who suggested 12 new outcomes for rating in Round 2. Sixty‐six percent of participants (30 parents and 66 professionals) completed Round 2, where 22 outcomes met criteria for inclusion. In the consensus meeting (nine parents and 13 professionals), 27 undecided outcomes were discussed and scored; one further outcome reached consensus for inclusion. After consultation and ratification, 14 outcomes across five domains were included in the core outcome set.Significance: A core outcome set for childhood epilepsy treated with KDT has been developed, incorporating the views of international parents and professionals. Implementation in research and clinical settings will standardize outcome selection and reporting, facilitate data synthesis, and ultimately enhance the relevance of outcomes to parents, researchers, and health professionals.
- Open Access
- 17 August 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-10
The CORE-KDT study: a mixed methods protocol to establish core outcomes for refractory childhood epilepsy treated with ketogenic diet therapy
Background: A core outcome set defines the minimum outcomes that should be included in clinical trials, audit or practice. The aim being to increase the quality and relevance of research by ensuring consistency in the measurement and reporting of outcomes. Core outcome sets have been developed for a variety of disease states and treatments. However, there is no established set of core outcomes for refractory childhood epilepsy treated with ketogenic diet therapy. This should be developed using a patient-centred approach to ensure the outcomes measured are relevant to patients and clinical practice. Methods: This is a mixed methods study of four phases to develop a core outcome set for refractory childhood epilepsy treated with ketogenic diet therapy. In phase 1, a systematic scoping review of the literature will establish which outcomes are measured in trials of refractory epilepsy treated with ketogenic diet therapy. In phase 2, qualitative interviews with parents and carers will aim to identify the outcomes of importance to these stakeholders. Phase 3 will see a comprehensive list of outcomes collated from the first two phases, grouped into domains according to an outcome taxonomy. Phase 4 will invite parents, health care professionals and researchers to participate in a two-round Delphi study to rate the importance of the presented outcomes. Following which, the core outcome set will be ratified at a face to face consensus meeting. Discussion: This study will guide outcome measurement in future studies of childhood epilepsy treated with ketogenic diet therapy and clinical practice through audit and service evaluation.
- 17 August 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-10
Open AccessThe CORE-KDT study: a mixed methods protocol to establish core outcomes for refractory childhood epilepsy treated with ketogenic diet therapy
Background: A core outcome set defines the minimum outcomes that should be included in clinical trials, audit or practice. The aim being to increase the quality and relevance of research by ensuring consistency in the measurement and reporting of outcomes. Core outcome sets have been developed for a variety of disease states and treatments. However, there is no established set of core outcomes for refractory childhood epilepsy treated with ketogenic diet therapy. This should be developed using a patient-centred approach to ensure the outcomes measured are relevant to patients and clinical practice. Methods: This is a mixed methods study of four phases to develop a core outcome set for refractory childhood epilepsy treated with ketogenic diet therapy. In phase 1, a systematic scoping review of the literature will establish which outcomes are measured in trials of refractory epilepsy treated with ketogenic diet therapy. In phase 2, qualitative interviews with parents and carers will aim to identify the outcomes of importance to these stakeholders. Phase 3 will see a comprehensive list of outcomes collated from the first two phases, grouped into domains according to an outcome taxonomy. Phase 4 will invite parents, health care professionals and researchers to participate in a two-round Delphi study to rate the importance of the presented outcomes. Following which, the core outcome set will be ratified at a face to face consensus meeting. Discussion: This study will guide outcome measurement in future studies of childhood epilepsy treated with ketogenic diet therapy and clinical practice through audit and service evaluation.
- Open Access
- 13 May 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 99, 54-67
Core outcome set development for childhood epilepsy treated with ketogenic diet therapy: Results of a scoping review and parent interviews
- 13 May 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 99, 54-67
Open AccessCore outcome set development for childhood epilepsy treated with ketogenic diet therapy: Results of a scoping review and parent interviews
- 20 August 2019
- Published by Wiley in Journal of Human Nutrition and Dietetics
- Vol. 33 (1) , 98-105
Nice to know: impact of NICE guidelines on ketogenic diet services nationwide
Background: In 2012, the National Institute for Health and Care Excellence (NICE) Clinical Guidelines for Epilepsies: Diagnosis and Management (CG137) included, for the first time, ketogenic diets (KDs) as a treatment option for drug‐resistant paediatric epilepsy. The recommendation was made to refer children and young people with epilepsy whose seizures have not responded to appropriate anti‐epileptic drugs to a tertiary paediatric epilepsy specialist for consideration of the use of KDs. We aimed to assess the impact of this change in guidance on the numbers of ketogenic centres and patients following KDs for epilepsy in the UK and Ireland.Methods: An online survey was circulated to ketogenic dietitians from the UK and Ireland. The results were compared with similar surveys published in 2000 and 2010. Results: The number of centres offering KDs for treatment of epilepsy has risen from 22 in 2000, to 28 in 2010, and to 39 in 2017 (77% overall increase). Seven of these centres accept adult referrals, in comparison to only two centres in 2010. Patient numbers have increased from 101 in 2000 to 754 in 2017. In total, 267 patients are waiting to commence KD at 31 centres.Conclusions: Over the last 7 years, the number of patients treated with a KD for epilepsy in the UK and Ireland has increased by 647%, with a 77% increase in the number of centres offering KDs. Despite this rapid growth, there is ongoing demand for patients to be considered for dietary therapy, highlighting the need for continued expansion of KD services nationally.
- 20 August 2019
- Published by Wiley in Journal of Human Nutrition and Dietetics
- Vol. 33 (1) , 98-105
Nice to know: impact of NICE guidelines on ketogenic diet services nationwide
Background: In 2012, the National Institute for Health and Care Excellence (NICE) Clinical Guidelines for Epilepsies: Diagnosis and Management (CG137) included, for the first time, ketogenic diets (KDs) as a treatment option for drug‐resistant paediatric epilepsy. The recommendation was made to refer children and young people with epilepsy whose seizures have not responded to appropriate anti‐epileptic drugs to a tertiary paediatric epilepsy specialist for consideration of the use of KDs. We aimed to assess the impact of this change in guidance on the numbers of ketogenic centres and patients following KDs for epilepsy in the UK and Ireland.Methods: An online survey was circulated to ketogenic dietitians from the UK and Ireland. The results were compared with similar surveys published in 2000 and 2010. Results: The number of centres offering KDs for treatment of epilepsy has risen from 22 in 2000, to 28 in 2010, and to 39 in 2017 (77% overall increase). Seven of these centres accept adult referrals, in comparison to only two centres in 2010. Patient numbers have increased from 101 in 2000 to 754 in 2017. In total, 267 patients are waiting to commence KD at 31 centres.Conclusions: Over the last 7 years, the number of patients treated with a KD for epilepsy in the UK and Ireland has increased by 647%, with a 77% increase in the number of centres offering KDs. Despite this rapid growth, there is ongoing demand for patients to be considered for dietary therapy, highlighting the need for continued expansion of KD services nationally.
- 1 May 2019
- Published by Wolters Kluwer Health in JBI Evidence Synthesis
- Vol. 17 (5) , 633-639
Outcome measurement and reporting in childhood epilepsy treated with ketogenic diet therapy: a scoping review protocol
Review objective/question: The objective of this scoping review is to investigate the outcomes measured and reported in trials of children with refractory epilepsy treated with ketogenic diet therapy. The scoping review will aim to list the outcomes and map the associated components including intervention (type of ketogenic diet therapy), definition (if used) of the outcome, the tool or indicators used to measure the outcome, validity of tool used, the time from intervention commencement to measurement of the outcome and the reporting of the outcome. Specifically, the review question is: What outcomes are measured and reported in studies of childhood epilepsy treated with ketogenic diet therapy?
- 1 May 2019
- Published by Wolters Kluwer Health in JBI Evidence Synthesis
- Vol. 17 (5) , 633-639
Outcome measurement and reporting in childhood epilepsy treated with ketogenic diet therapy: a scoping review protocol
Review objective/question: The objective of this scoping review is to investigate the outcomes measured and reported in trials of children with refractory epilepsy treated with ketogenic diet therapy. The scoping review will aim to list the outcomes and map the associated components including intervention (type of ketogenic diet therapy), definition (if used) of the outcome, the tool or indicators used to measure the outcome, validity of tool used, the time from intervention commencement to measurement of the outcome and the reporting of the outcome. Specifically, the review question is: What outcomes are measured and reported in studies of childhood epilepsy treated with ketogenic diet therapy?